BCRX – BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.BCRX
$7.40Name : BioCryst Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $1,546,304,000.00
EPSttm : -0.43
BioCryst Pharmaceuticals, Inc.
$7.40
2.49%$0.18Float Short %
10.51
Margin Of Safety %
Put/Call OI Ratio
0.34
EPS Next Q Diff
0.12
EPS Last/This Y
0.38
EPS This/Next Y
0.37
Price
7.4
Target Price
14.73
Analyst Recom
1.18
Performance Q
4.82
Relative Volume
0.99
Beta
1.09
Ticker: BCRX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-20 | BCRX | 7.69 | 0.30 | 0.26 | 32318 |
| 2025-03-21 | BCRX | 7.99 | 0.30 | 0.03 | 32167 |
| 2025-03-24 | BCRX | 8.05 | 0.34 | 0.17 | 23508 |
| 2025-03-25 | BCRX | 8.08 | 0.34 | 1.82 | 24187 |
| 2025-03-26 | BCRX | 7.81 | 0.34 | 0.31 | 24309 |
| 2025-03-27 | BCRX | 7.82 | 0.35 | 1.42 | 24433 |
| 2025-03-28 | BCRX | 7.86 | 0.35 | 0.45 | 24600 |
| 2025-03-31 | BCRX | 7.51 | 0.35 | 0.48 | 24695 |
| 2025-04-01 | BCRX | 7.24 | 0.36 | 0.14 | 24828 |
| 2025-04-02 | BCRX | 7.42 | 0.35 | 0.30 | 24790 |
| 2025-04-03 | BCRX | 7.32 | 0.36 | 4.01 | 24877 |
| 2025-04-04 | BCRX | 6.84 | 0.37 | 0.11 | 25312 |
| 2025-04-07 | BCRX | 6.78 | 0.37 | 0.00 | 25777 |
| 2025-04-08 | BCRX | 6.48 | 0.32 | 0.10 | 28533 |
| 2025-04-09 | BCRX | 6.76 | 0.31 | 1.01 | 28399 |
| 2025-04-10 | BCRX | 6.41 | 0.31 | 0.37 | 28406 |
| 2025-04-11 | BCRX | 6.82 | 0.31 | 0.26 | 28471 |
| 2025-04-14 | BCRX | 7.04 | 0.31 | 0.16 | 28431 |
| 2025-04-15 | BCRX | 7.4 | 0.31 | 0.73 | 28570 |
| 2025-04-16 | BCRX | 7.23 | 0.34 | 0.41 | 29353 |
| 2025-04-17 | BCRX | 7.41 | 0.34 | 0.01 | 29719 |
| 2025-04-18 | BCRX | 7.4 | 0.34 | 0.01 | 29719 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-20 | BCRX | 7.69 | 69.4 | - | -0.07 |
| 2025-03-21 | BCRX | 7.99 | 69.4 | - | -0.07 |
| 2025-03-24 | BCRX | 8.05 | 69.4 | - | -0.07 |
| 2025-03-25 | BCRX | 8.07 | 69.4 | - | -0.07 |
| 2025-03-26 | BCRX | 7.80 | 69.4 | - | -0.07 |
| 2025-03-27 | BCRX | 7.82 | 69.4 | - | -0.07 |
| 2025-03-28 | BCRX | 7.86 | 69.4 | - | -0.07 |
| 2025-03-31 | BCRX | 7.51 | 69.4 | - | -0.07 |
| 2025-04-01 | BCRX | 7.25 | 69.4 | - | -0.07 |
| 2025-04-02 | BCRX | 7.43 | 69.4 | - | -0.07 |
| 2025-04-03 | BCRX | 7.32 | 69.4 | - | -0.07 |
| 2025-04-04 | BCRX | 6.83 | 69.4 | - | -0.07 |
| 2025-04-07 | BCRX | 6.79 | 69.4 | - | -0.06 |
| 2025-04-08 | BCRX | 6.47 | 69.4 | - | -0.06 |
| 2025-04-09 | BCRX | 6.77 | 69.4 | - | -0.06 |
| 2025-04-10 | BCRX | 6.41 | 69.4 | - | -0.06 |
| 2025-04-11 | BCRX | 6.82 | 69.4 | - | -0.06 |
| 2025-04-14 | BCRX | 7.04 | 69.4 | - | -0.06 |
| 2025-04-15 | BCRX | 7.40 | 69.4 | - | -0.06 |
| 2025-04-16 | BCRX | 7.23 | 69.4 | - | -0.06 |
| 2025-04-17 | BCRX | 7.40 | 69.4 | - | -0.05 |
| 2025-04-18 | BCRX | 7.40 | 69.4 | - | -0.05 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-20 | BCRX | -0.06 | -3.29 | 8.12 |
| 2025-03-21 | BCRX | -0.06 | -3.29 | 8.12 |
| 2025-03-24 | BCRX | -0.06 | -3.29 | 8.12 |
| 2025-03-25 | BCRX | -0.06 | -3.29 | 8.12 |
| 2025-03-26 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-03-27 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-03-28 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-03-31 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-04-01 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-04-02 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-04-03 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-04-04 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-04-07 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-04-08 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-04-09 | BCRX | -0.06 | -3.29 | 10.03 |
| 2025-04-10 | BCRX | -0.06 | -3.29 | 10.51 |
| 2025-04-11 | BCRX | -0.06 | -3.29 | 10.51 |
| 2025-04-14 | BCRX | -0.06 | -3.27 | 10.51 |
| 2025-04-15 | BCRX | -0.06 | -3.27 | 10.51 |
| 2025-04-16 | BCRX | -0.06 | -3.27 | 10.51 |
| 2025-04-17 | BCRX | -0.06 | -3.27 | 10.51 |
| 2025-04-18 | BCRX | -0.06 | -3.27 | 10.51 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.13
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.01
Insider Transactions
-0.06
Institutional Transactions
-3.27
Beta
1.09
Average Sales Estimate Current Quarter
126
Average Sales Estimate Next Quarter
139
Fair Value
Quality Score
50
Growth Score
55
Sentiment Score
93
Actual DrawDown %
63
Max Drawdown 5-Year %
-79.1
Target Price
14.73
P/E
Forward P/E
34.2
PEG
P/S
3.43
P/B
P/Free Cash Flow
EPS
-0.43
Average EPS Est. Cur. Y
-0.05
EPS Next Y. (Est.)
0.32
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-19.72
Relative Volume
0.99
Return on Equity vs Sector %
-1.3
Return on Equity vs Industry %
10.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
BioCryst Pharmaceuticals, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 580
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
stock quote shares BCRX – BioCryst Pharmaceuticals, Inc. Stock Price stock today
news today BCRX – BioCryst Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BCRX – BioCryst Pharmaceuticals, Inc. yahoo finance google finance
stock history BCRX – BioCryst Pharmaceuticals, Inc. invest stock market
stock prices BCRX premarket after hours
ticker BCRX fair value insiders trading